Kyntra Bio (KYNB) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $213.8 million.

  • Kyntra Bio's Income towards Parent Company rose 58502.31% to $213.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.9 million, marking a year-over-year increase of 200347.42%. This contributed to the annual value of $105.5 million for FY2024, which is 17239.15% up from last year.
  • Latest data reveals that Kyntra Bio reported Income towards Parent Company of $213.8 million as of Q3 2025, which was up 58502.31% from $6.1 million recorded in Q2 2025.
  • Kyntra Bio's Income towards Parent Company's 5-year high stood at $213.8 million during Q3 2025, with a 5-year trough of -$134.5 million in Q2 2021.
  • Moreover, its 5-year median value for Income towards Parent Company was -$64.3 million (2023), whereas its average is -$29.6 million.
  • In the last 5 years, Kyntra Bio's Income towards Parent Company crashed by 28613.92% in 2022 and then soared by 58502.31% in 2025.
  • Kyntra Bio's Income towards Parent Company (Quarter) stood at -$134.4 million in 2021, then soared by 50.56% to -$66.5 million in 2022, then plummeted by 39.86% to -$92.9 million in 2023, then skyrocketed by 128.67% to $26.6 million in 2024, then surged by 702.27% to $213.8 million in 2025.
  • Its Income towards Parent Company stands at $213.8 million for Q3 2025, versus $6.1 million for Q2 2025 and $21.4 million for Q1 2025.